• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大鼠血脑脊髓液屏障转运蛋白的定量靶向绝对蛋白质组学:与人类样本的比较。

Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with a human specimen.

作者信息

Uchida Yasuo, Zhang Zhengyu, Tachikawa Masanori, Terasaki Tetsuya

机构信息

Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.

出版信息

J Neurochem. 2015 Sep;134(6):1104-15. doi: 10.1111/jnc.13147. Epub 2015 Jun 8.

DOI:10.1111/jnc.13147
PMID:25951748
Abstract

The purpose of this study was to determine absolute protein expression levels of transporters in rat choroid plexus, that is, the blood-cerebrospinal fluid barrier, and to compare them with the levels in the human choroid plexus. Plasma membrane fractions were prepared from pooled, freshly isolated choroid plexuses of 30 male Wistar rats and from frozen choroid plexus of one male human donor. Protein expression levels of 54 rat and 121 human molecules were measured, using a quantitative targeted absolute proteomics technique. In rat, oatp1a5 showed the most abundant protein expression (30.3 fmol/μg protein), and its expression level was 3.1-, 4.5-, 5.5-, 8.4-, 9.0-, 9.9-, 22-, 91-, and 95-fold greater than those of glut1, oatp1c1, mrp1, mct1, oat3, pept2, mrp4, bcrp, and mdr1a, respectively. OATP1A2 (a possible homolog of rat oatp1a5), OATP1C1 and PEPT2 were not detected in human choroid plexus. MRP1, OAT3, and MRP4 showed 4.0-, 1.8-, and 1.7-fold smaller expression levels in human than rat, respectively. MATE1 was detected in human, but not rat, and its expression level (8.61 fmol/μg protein) was the highest among the xenobiotic transporters examined in human choroid plexus. These findings should be useful for understanding rat blood-cerebrospinal fluid barrier function and its differences from that in human. This is the first study clarifying the absolute protein expression levels of many transporters in the plasma membrane fractions of rat and human choroid plexuses, that is, blood cerebrospinal fluid barrier, by means of quantitative targeted absolute proteomics (QTAP) technique. This study also identified the protein expressions of some transporters including MATE1 and ABCA8 in the choroid plexus for the first time.

摘要

本研究的目的是确定大鼠脉络丛(即血脑脊髓液屏障)中转运蛋白的绝对蛋白表达水平,并将其与人类脉络丛中的水平进行比较。从30只雄性Wistar大鼠新鲜分离的合并脉络丛以及一名男性人类供体的冷冻脉络丛中制备质膜组分。使用定量靶向绝对蛋白质组学技术测量了54种大鼠和121种人类分子的蛋白质表达水平。在大鼠中,oatp1a5显示出最丰富的蛋白质表达(30.3 fmol/μg蛋白质),其表达水平分别比glut1、oatp1c1、mrp1、mct1、oat3、pept2、mrp4、bcrp和mdr1a高3.1倍、4.5倍、5.5倍、8.4倍、9.0倍、9.9倍、22倍、91倍和95倍。在人类脉络丛中未检测到OATP1A2(大鼠oatp1a5的可能同源物)、OATP1C1和PEPT2。MRP1、OAT3和MRP4在人类中的表达水平分别比大鼠低4.0倍、1.8倍和1.7倍。在人类中检测到了MATE1,但在大鼠中未检测到,其表达水平(8.61 fmol/μg蛋白质)在人类脉络丛中检测的外源性转运蛋白中最高。这些发现对于理解大鼠血脑脊髓液屏障功能及其与人类的差异应该是有用的。这是第一项通过定量靶向绝对蛋白质组学(QTAP)技术阐明大鼠和人类脉络丛(即血脑脊髓液屏障)质膜组分中许多转运蛋白绝对蛋白表达水平的研究。本研究还首次鉴定了脉络丛中包括MATE1和ABCA8在内的一些转运蛋白的蛋白质表达。

相似文献

1
Quantitative targeted absolute proteomics of rat blood-cerebrospinal fluid barrier transporters: comparison with a human specimen.大鼠血脑脊髓液屏障转运蛋白的定量靶向绝对蛋白质组学:与人类样本的比较。
J Neurochem. 2015 Sep;134(6):1104-15. doi: 10.1111/jnc.13147. Epub 2015 Jun 8.
2
Abundant Expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1, and xCT Transporters in Blood-Arachnoid Barrier of Pig and Polarized Localizations at CSF- and Blood-Facing Plasma Membranes.在猪的血-蛛网膜屏障中大量表达 OCT2、MATE1、OAT1、OAT3、PEPT2、BCRP、MDR1 和 xCT 转运体,并在 CSF-和血液-面对的质膜上呈现极化定位。
Drug Metab Dispos. 2020 Feb;48(2):135-145. doi: 10.1124/dmd.119.089516. Epub 2019 Nov 26.
3
Drug Clearance from Cerebrospinal Fluid Mediated by Organic Anion Transporters 1 (Slc22a6) and 3 (Slc22a8) at Arachnoid Membrane of Rats.有机阴离子转运体 1(Slc22a6)和 3(Slc22a8)介导的药物从大鼠蛛网膜脑脊液清除。
Mol Pharm. 2018 Mar 5;15(3):911-922. doi: 10.1021/acs.molpharmaceut.7b00852. Epub 2018 Feb 21.
4
Inner Blood-Retinal Barrier Dominantly Expresses Breast Cancer Resistance Protein: Comparative Quantitative Targeted Absolute Proteomics Study of CNS Barriers in Pig.内在血-视网膜屏障主要表达乳腺癌耐药蛋白:猪中枢神经系统屏障的比较定量靶向绝对蛋白质组学研究。
Mol Pharm. 2017 Nov 6;14(11):3729-3738. doi: 10.1021/acs.molpharmaceut.7b00493. Epub 2017 Oct 12.
5
Quantitative Targeted Absolute Proteomics for 28 Transporters in Brush-Border and Basolateral Membrane Fractions of Rat Kidney.大鼠肾脏刷状缘和基底外侧膜组分中28种转运蛋白的定量靶向绝对蛋白质组学
J Pharm Sci. 2016 Feb;105(2):1011-1016. doi: 10.1002/jps.24645. Epub 2016 Jan 11.
6
Developmental changes in transporter and receptor protein expression levels at the rat blood-brain barrier based on quantitative targeted absolute proteomics.基于定量靶向绝对蛋白质组学的大鼠血脑屏障转运体和受体蛋白表达水平的发育变化。
Drug Metab Pharmacokinet. 2020 Feb;35(1):117-123. doi: 10.1016/j.dmpk.2019.09.003. Epub 2019 Sep 27.
7
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors.人血脑屏障转运体和受体的定量靶向绝对蛋白质组学。
J Neurochem. 2011 Apr;117(2):333-45. doi: 10.1111/j.1471-4159.2011.07208.x. Epub 2011 Feb 25.
8
Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates.犬脑毛细血管和脉络丛中转运体和受体蛋白的定量:对选定的 BCRP 和 P-糖蛋白底物在脑和 CSF 中分布的相关性。
Mol Pharm. 2017 Oct 2;14(10):3436-3447. doi: 10.1021/acs.molpharmaceut.7b00449. Epub 2017 Sep 19.
9
Role of cationic drug-sensitive transport systems at the blood-cerebrospinal fluid barrier in para-tyramine elimination from rat brain.血脑屏障中阳离子药物敏感转运系统在对苯甲胺从大鼠脑中消除的作用。
Fluids Barriers CNS. 2018 Jan 8;15(1):1. doi: 10.1186/s12987-017-0087-9.
10
Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats.大鼠脉络丛中各种外源性和内源性生物转运体mRNA的组成性表达。
Drug Metab Dispos. 2003 Nov;31(11):1337-45. doi: 10.1124/dmd.31.11.1337.

引用本文的文献

1
Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood-Brain Barrier and Blood-Tumor Barrier.超越特洛伊城墙:关于增强药物透过血脑屏障和血肿瘤屏障递送的药理学策略的范围综述
Int J Mol Sci. 2025 Jul 22;26(15):7050. doi: 10.3390/ijms26157050.
2
Molecular determinants of neuroprotection in blood-brain interfaces of the cynomolgus monkey.食蟹猴血脑界面神经保护的分子决定因素
Front Pharmacol. 2025 Mar 12;16:1523819. doi: 10.3389/fphar.2025.1523819. eCollection 2025.
3
Molecular dynamics simulation of the brain-isolated single-domain antibody/nanobody from camels through phage display screening.
通过噬菌体展示筛选对骆驼脑分离单域抗体/纳米抗体进行分子动力学模拟。
Front Mol Biosci. 2024 Sep 2;11:1414119. doi: 10.3389/fmolb.2024.1414119. eCollection 2024.
4
Mechanisms of cerebrospinal fluid secretion by the choroid plexus epithelium: Application to various intracranial pathologies.脉络丛上皮分泌脑脊液的机制:在各种颅内病变中的应用
Clin Anat. 2025 Jan;38(1):63-74. doi: 10.1002/ca.24199. Epub 2024 Jun 19.
5
Transporters, Ion Channels, and Junctional Proteins in Choroid Plexus Epithelial Cells.脉络丛上皮细胞中的转运体、离子通道和连接蛋白
Biomedicines. 2024 Mar 22;12(4):708. doi: 10.3390/biomedicines12040708.
6
Metabolite transport across central nervous system barriers.代谢物穿过中枢神经系统屏障的转运。
J Cereb Blood Flow Metab. 2024 Jul;44(7):1063-1077. doi: 10.1177/0271678X241241908. Epub 2024 Mar 28.
7
Uptake Transporters at the Blood-Brain Barrier and Their Role in Brain Drug Disposition.血脑屏障处的摄取转运体及其在脑内药物处置中的作用。
Pharmaceutics. 2023 Oct 16;15(10):2473. doi: 10.3390/pharmaceutics15102473.
8
Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier.血脑屏障中 P-糖蛋白和 Bcrp 的功能评估。
Pharm Res. 2023 Nov;40(11):2667-2675. doi: 10.1007/s11095-023-03598-7. Epub 2023 Sep 13.
9
Molecular Mechanisms of Organic Anion Transporting Polypeptide-Mediated Organic Anion Clearance at the Blood-Cerebrospinal Fluid Barrier.有机阴离子转运多肽介导的血脑屏障有机阴离子清除的分子机制。
Mol Pharmacol. 2023 Dec;104(6):255-265. doi: 10.1124/molpharm.123.000703. Epub 2023 Aug 31.
10
Distribution of Monocarboxylate Transporters in Brain and Choroid Plexus Epithelium.单羧酸转运体在脑和脉络丛上皮中的分布。
Pharmaceutics. 2023 Jul 31;15(8):2062. doi: 10.3390/pharmaceutics15082062.